



ACN 007 988 767  
Phone: +61 8 8234 2660  
Fax: +61 8 8234 6268  
Address: 38 Winwood Street  
Thebarton South Australia 5031  
www.bresagen.com

02 JUN -7 AM 11:21

82-5135

**FACSIMILE TRANSMISSION**

**TO:** The Office of International Corporate Finance  
**COMPANY:** SEC  
**FAX NUMBER:** 0011 1 202 942 9624  
**FROM:** Trudy Fenton  
**DATE:** Friday, 7 June 2002  
**SUBJECT:** ASX Announcement  
**PAGES (inc. cover)** 3

SUPPL



02034747

In accordance with our obligation as a 12g3-2(b) filer, number 82-5135, to file home country announcements, please find the following announcements which were released through the Australian Stock Exchange today –

1. Australian biotechs, BresaGen and EvoGenix working together.
2. BresaGen congratulates oward on stem cell research centre.

PROCESSED

JUN 13 2002

Yours sincerely

THOMSON  
FINANCIAL

*T. M. Fenton*

**Trudy Fenton**  
Corporate Administrator  
tfenton@bresagen.com.au

*dlw 6/10*

If there are any problems with this transmission, call 08 8234 2660

*This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution this information or any information this facsimile may contain by anyone other than the addressee, is prohibited. If you have received this document in error, please advise BresaGen by telephone and then return it by mail to the address above. We shall refund in full your costs in doing so.*

Thursday, 6 June 2002



## **BresaGen congratulates Howard on stem cell research centre**

Adelaide-based biotechnology company BresaGen Ltd has congratulated John Howard and the Federal Government on its support and vision in awarding a \$46 million funding package for stem-cell research.

The five year funding for the Biotechnology Centre of Excellence will go to the Centre for Stem Cells and Tissue Repair based at Monash, headed by Professor Alan Trounson. The Centre is made up of 17 commercial and academic groups including BresaGen and ES Cell International, two of the 10 groups with stem cell lines listed on the US National Institutes of Health (NIH) Stem Cell Registry.

BresaGen Chief Executive, Dr John Smeaton praised Professor Trounson for managing to bring the different groups together to work in the important area of stem cell research and therapy.

"We are looking forward to working with Professor Trounson and to hastening the development of commercially viable treatments for debilitating conditions such as Parkinson's Disease and spinal cord injury. BresaGen and ES Cell International, as the commercial partners, have worked together with Professor Trounson and Monash closely in the establishment of the associated National Centre for Advanced Cell Engineering which will be part of the Biotechnology Centre of Excellence. The two companies will bring their commercial expertise to help the Centre's academic participants in commercialising the new Intellectual Property which is expected to arise.

"BresaGen has considerable Intellectual Property which it is willing to make available to the Centre. We see this as an excellent opportunity for commercial and academic interests working together," said Dr Smeaton.

"We are also optimistic that the forthcoming Federal legislation on stem cells will be less restrictive and more commercially relevant."

*ends*

### **For further information contact:**

**Hilarie Dunn**  
**Public Relations**  
**BresaGen Ltd**  
**Ph: 02 92510110**  
**Mob: 0414 357792**

**or**

**Chris Juttner**  
**VP, Clinical Development**  
**BresaGen Ltd**  
**Ph: 08 8234 2660**  
**Mob: 0408 185 100**

Thursday, 6 June 2002



## **Australian biotechs, BresaGen and EvoGenix working together**

With complementary knowledge and skills, Adelaide-based biotechnology company, BresaGen Limited and the recently established company EvoGenix Pty Ltd have agreed to work together on a protein biopharmaceutical project which will advance the abilities of EvoGenix to progress one of its key technologies.

BresaGen will conduct feasibility studies and process development for a class of small protein molecules which EvoGenix plans to develop as an entirely new approach to finding and treating difficult targets such as viruses and cancer. BresaGen's expertise in process development for producing protein pharmaceuticals will be applied to finding an effective way of making the targeting proteins reliably and cheaply.

BresaGen is a company listed on the ASX, with operations in Adelaide and Athens, Georgia. The Company is focussed on development of protein drugs and treatments based on cell therapy.

EvoGenix is an early stage biotechnology company established to exploit novel technologies developed by the Cooperative Research Centre for Diagnostics.

With operations in Melbourne and Sydney, it is positioned within the fast growing field of protein biopharmaceuticals, offering a technology platform for the rapid identification and development of highly active proteins for use in human therapy and medical imaging.

Merilyn Sleigh, EvoGenix CEO, said: "Commentators on the Australian biotechnology industry question how all of the new companies being established will thrive and grow. One very powerful solution to this problem will be for Australian Biotechnology companies to work together to make the most of the considerable expertise available. I am delighted that we are able to work with BresaGen in this context, drawing from their substantial achievements in protein production methods to accelerate the development of our own key technologies."

"Agreements with companies like EvoGenix validate the process development capabilities engineered at BresaGen over the last 5 years" said John Smeaton, CEO of BresaGen. "We are delighted to be working with the emerging companies in the biotech sector".

*Ends*

**For more information contact:  
Meera Verma  
Chief Operating Officer  
BresaGen Limited  
08 8150 8220**